Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: A retrospective study

Nephrology Dialysis Transplantation

Volumn 20, Issue 9, 2005, Pages 1813-1820

  Kiser, Tyree H ^a   Fish, Douglas N ^a   Obritsch, Marilee D ^a   Jung, Rose ^a   MacLaren, Robert ^a   Parikh, Chirag R ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Acute renal failure; Cirrhosis; Dopamine; Mortality; Recovery; Response

Indexed keywords

CREATININE; OCTREOTIDE; ORNIPRESSIN; TERLIPRESSIN; VASOPRESSIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; COHORT STUDIES; FEMALE; HEPATORENAL SYNDROME; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; RETROSPECTIVE STUDIES;

EID: 24044507953     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh930     Document Type: Article

References (20)

1. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236
2. Rimola A, Gavaler JS, Schade RR et al. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148-156
3. Restuccia T, Ortega R, Guevara M et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-146
4. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
5. Brooks DP, Share L, Crofton JT. Central adrenergic control of vasopressin release. Neuroendocrinology 1986; 42: 416-420
6. Guevara M, Gines P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41
7. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-875
8. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48
9. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-158
10. Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948
11. Solanki P, Chawla A, Garg R et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156
12. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-1697
13. Guevara M, Gines P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-422
14. Angeli P, Volpin R, Piovan D et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937-943
15. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64
16. Pomier-Layrargues G, Paquin SC, Hassoun Z et al. Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38: 238-243
17. Dunser MW, Mayr AJ, Tur A et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003; 31: 1394-1398
18. Obritsch MD, Jung R, Fish DN et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004; 38: 1117-1122
19. Malay MB, Ashton JL, Dahl K et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32: 1327-1331
20. Moller S, Brinch K, Henriksen JH et al. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997; 26: 1026-1033